Sun Pharmaceutical Industries is aiming to gain market share in all the verticals it is present in amid challenges posed by the coronavirus pandemic. The drug major, which has presence in around 150 countries, caters to various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others.
The company is also looking at supply chain protection, ensuring optimum utilisation of its factories and working closely with vendors to ensure continuity of supply while at the same time continuing focus on improving productivity throughout. In times of COVID-19, the company also looks to focus on cash preservation and finding a way to reduce the overall debt for the company.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
